AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36817 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate, 0.3 mg IM, 1 hr before induction of anesthesia
Number of subjects: 23
Study 31703925 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified ceramic crowns (RMC group)
Number of subjects: 42
Study 31703925 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns (MC group)
Number of subjects: 42
Study 31703925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both crown types
Number of subjects: 42
Study 31198477 — intervention group
Group type: EXPERIMENTAL
Intervention: ELIBA device (lingual elevator by Balercia) used for at least 16 h/day for 6 months
Number of subjects: 50
Study 28264684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 231
Study 28264684 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 231
Study 23922258 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 20
Study 23922258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23109266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 30
Study 23109266 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 30
Study 21854609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 771)
Number of subjects: 1518
Study 21854609 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 747)
Number of subjects: 1518
Study 20180356 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg once daily
Number of subjects: 102
Study 20180356 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 35 mg once a week
Number of subjects: 102
Study 16540851 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg x kg(‐1) body weight
Number of subjects: 11
Study 16540851 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg x kg(‐1) body weight
Number of subjects: 11
Study 16540851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 14734986 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze dressing
Number of subjects: 78
Study 14734986 — intervention group
Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 78
Study 11680666 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan + Diuretic (L+D)
Number of subjects: 37
Study 11680666 — intervention group
Group type: COMPARATOR
Intervention: Calcium Channel Blocker + Diuretic (N+D)
Number of subjects: 37
Study 9270666 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) (1.5 g i.v. followed by infusion of 1 mg/kg/min for 30 min, n = 10)
Number of subjects: 28
Study 9270666 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g i.v. followed by infusion of 0.65 mg/kg/min for 30 min, n = 6)
Number of subjects: 28
Study 9270666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 28
Study 8197037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 1 g plus metronidazole 500 mg intravenously every 12 hours
Number of subjects: 18
Study 8197037 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 2 g intravenously every 6 hours
Number of subjects: 18
Study 8197037 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam 3 g every 6 hours
Number of subjects: 18
Study 2454360 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 15
Study 2454360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30430875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination topical gel of nifedipine (NIF), lidocaine hydrochloride (LDH), and betamethasone valerate (BMV)
Number of subjects: 71
Study 30430875 — intervention group
Group type: COMPARATOR
Intervention: Market products (single drug treatments)
Number of subjects: 71
Study 27435332 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg intravenous tranexamic acid (TXA)
Number of subjects: 70
Study 27435332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 70
Study 24092662 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 75/25 (LM75/25)
Number of subjects: 0
Study 24092662 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 0
Study 22538054 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (3mg) infused locally in the proximal jejunum after administering ketoconazole (doses ranging from 1-128 mg, with an oral dose of 200mg given 12h earlier)
Number of subjects: 8
Study 22538054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (up to 16 mg)
Number of subjects: 8
Study 22538054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (64 mg and above)
Number of subjects: 8
Study 22538054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (1 mg in mucosa and 50 mg in liver)
Number of subjects: 8
Study 22538054 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (0.2mg) administered intravenously
Number of subjects: 8
Study 19640853 — intervention group
Group type: COMPARATOR
Intervention: Onercept 50 mg and 100 mg
Number of subjects: 297
Study 19640853 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 297
Study 18545216 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal heating and humidification in elderly subjects
Number of subjects: 80
Study 18545216 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger subjects)
Number of subjects: 80
Study 18545216 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (elderly subjects)
Number of subjects: 80
Study 15572317 — intervention group
Group type: EXPERIMENTAL
Intervention: Braced group (off-the-shelf functional knee brace for all cutting, pivoting, or jumping activities for the first year after surgery)
Number of subjects: 100
Study 15572317 — intervention group
Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 100
Study 11689747 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe inserts with varying shape and material (hardness, elasticity)
Number of subjects: 206
Study 11689747 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe inserts
Number of subjects: 206
Study 11689747 — intervention group
Group type: COMPARATOR
Intervention: No insert (control condition)
Number of subjects: 206
Study 9329640 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro irradiation
Number of subjects: 2
Study 9329640 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cells of patients subjected to radioiodine therapy
Number of subjects: 2
Study 9329640 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cells of chronically irradiated volunteers from the Chernobyl region
Number of subjects: 2
Study 9329640 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 8137969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast media
Number of subjects: 2606
Study 8137969 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble contrast media
Number of subjects: 2606
Study 2906317 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 2906317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29338917 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 30
Study 29338917 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Number of subjects: 30
Study 29338917 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no supervised exercise)
Number of subjects: 30
Study 27020633 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Palm Oil (RPO)
Number of subjects: 60
Study 27020633 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 60
Study 24955450 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole and flupentixol/melitracen (combination therapy)
Number of subjects: 289
Study 24955450 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole only (monotherapy)
Number of subjects: 289
Study 23372114 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r 800/100 mg once daily)
Number of subjects: 256
Study 23372114 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with darunavir/ritonavir + 2 NRTIs
Number of subjects: 256
Study 20566975 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior 90 degrees partial fundoplication
Number of subjects: 112
Study 20566975 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 112
Study 18579383 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) of hamstring muscles during quiet standing in different degrees of crouch
Number of subjects: 5
Study 16998862 — intervention group
Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB) severity scores
Number of subjects: 12750
Study 16998862 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence (SUI) severity scores
Number of subjects: 12750
Study 16998862 — intervention group
Group type: EXPERIMENTAL
Intervention: SUI severity scores
Number of subjects: 12750
Study 16998862 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion validity of OAB and SUI severity scores
Number of subjects: 12750
Study 14520123 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 24
Study 14520123 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg/d
Number of subjects: 24
Study 10926339 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg inhaled budesonide per day
Number of subjects: 101
Study 10926339 — intervention group
Group type: COMPARATOR
Intervention: 200 microg inhaled budesonide per day
Number of subjects: 101
Study 8885772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 60
Study 8885772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8885772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin and Placebo
Number of subjects: 60
Study 1389761 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 20 mg
Number of subjects: 23
Study 1389761 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 23
Study 1389761 — intervention group
Group type: COMPARATOR
Intervention: Combination of Atenolol and Nifedipine
Number of subjects: 23
Study 1389761 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study 4017661 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin group (ALB) received 80 g albumin on the day of operation and 20 g albumin for the following three days.
Number of subjects: 26
Study 4017661 — intervention group
Group type: COMPARATOR
Intervention: Control group (NON-ALB) received no extra albumin.
Number of subjects: 26
Study 4017661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ALB and NON-ALB)
Number of subjects: 26
Study 4017661 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 26
Study 30657719 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing an 18.10-kg weight vest (W)
Number of subjects: 50
Study 30657719 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 50
Study 30413176 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app with personalized motivational messages via a recommender system for 6 months
Number of subjects: 200
Study 30413176 — intervention group
Group type: COMPARATOR
Intervention: Basic motivational messages
Number of subjects: 200
Study 27136347 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 220
Study 27136347 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AL)
Number of subjects: 220
Study 24331842 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (50 μg/kg/min loading dose followed by 0.6 μg/kg/min continuous infusion)
Number of subjects: 40
Study 24331842 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (identical volume infused in the same fashion)
Number of subjects: 40
Study 22251615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg daily
Number of subjects: 763
Study 22251615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763
Study 22251615 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 763
Study 20149690 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE) with Bead Block
Number of subjects: 23
Study 17629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (Group A, n=63)
Number of subjects: 120
Study 17629829 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection system (Group B, n=57)
Number of subjects: 120
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol biopsy (n = 30)
Number of subjects: 59
Study 12595513 — intervention group
Group type: COMPARATOR
Intervention: No-biopsy (n = 29)
Number of subjects: 59
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (n = 5)
Number of subjects: 59
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA discontinuation/reduction (n = 13)
Number of subjects: 59
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (n = 12)
Number of subjects: 59
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering CsA to low target trough (30 to 70 ng/ml)
Number of subjects: 59
Study 12595513 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (biopsy patients)
Number of subjects: 59
Study 11039423 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane differential filtration treatment, administered five times over a period of 21 weeks.
Number of subjects: 40
Study 11039423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 40
Study 11039423 — intervention group
Group type: EXPERIMENTAL
Intervention: Membrane differential filtration treatment.
Number of subjects: 40
Study 9020990 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirlindole (300 mg/day)
Number of subjects: 103
Study 9020990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 1547164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission for rest
Number of subjects: 218
Study 1547164 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient care (Control)
Number of subjects: 218
Study 2864741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g sulphasalazine daily
Number of subjects: 30
Study 2864741 — intervention group
Group type: COMPARATOR
Intervention: 500 mg penicillamine daily
Number of subjects: 30
Study 30463479 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-volume HIIT (4-6 work bouts of 60 seconds with 75 seconds of low-intensity recovery)
Number of subjects: 23
Study 30463479 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-volume HIIT
Number of subjects: 23
Study 30463479 — intervention group
Group type: COMPARATOR
Intervention: Low-volume HIIT (8-12 work bouts of 60 seconds with 75 seconds of low-intensity recovery)
Number of subjects: 23
Study 30463479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 23
Study 28657793 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 0
Study 28657793 — intervention group
Group type: COMPARATOR
Intervention: Control (no simvastatin)
Number of subjects: 0
Study 25887355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA1c goal < 6%)
Number of subjects: 10251
Study 25887355 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (HbA1c goal 7.0% to 7.9%)
Number of subjects: 10251
Study 24124951 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual diabetes educational activity
Number of subjects: 92
Study 21438849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg
Number of subjects: 12
Study 19568175 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to women unaware of their HIV status
Number of subjects: 2435
Study 19568175 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) administration to women who tested positive for HIV
Number of subjects: 2435
Study 19568175 — intervention group
Group type: COMPARATOR
Intervention: Inert (calcium) tablet provided to women who tested negative for HIV
Number of subjects: 2435
Study 17364309 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial coagulation
Number of subjects: 120
Study 17364309 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 120
Study 17364309 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation (combined results)
Number of subjects: 120
Study 17364309 — intervention group
Group type: EXPERIMENTAL
Intervention: No further intervention at two-year follow-up
Number of subjects: 120
Study 15298426 — intervention group
Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator
Number of subjects: 0
Study 15298426 — intervention group
Group type: COMPARATOR
Intervention: Duraflo II-coated CPB system
Number of subjects: 0
Study 15298426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 10993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 284
Study 10993130 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 284
Study 8817259 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous muscle activation during force pulses and steps
Number of subjects: 9
Study 8817259 — intervention group
Group type: EXPERIMENTAL
Intervention: Phasic and tonic EMG activity comparison
Number of subjects: 9
Study 1585511 — intervention group
Group type: EXPERIMENTAL
Intervention: M-VAC chemotherapy
Number of subjects: 18
Study 1585511 — intervention group
Group type: COMPARATOR
Intervention: CisCA chemotherapy
Number of subjects: 18
Study 2857602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 2857602 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 10
Study 2857602 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 10
Study 28436756 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Adolescents (IPT-A)
Number of subjects: 40
Study 30192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Hilotherm cooling system
Number of subjects: 34
Study 30192290 — intervention group
Group type: COMPARATOR
Intervention: Control group without cooling system
Number of subjects: 34
Study 27704507 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU bolus of Oxytocin + 25 IU IVD in 500 ml of serum over 3 hours
Number of subjects: 87
Study 27704507 — intervention group
Group type: COMPARATOR
Intervention: 5 IU IVD of Oxytocin + 25 IU in 500 ml serum over 3 hours
Number of subjects: 87
Study 24667132 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched rice (80 g daily)
Number of subjects: 20
Study 24667132 — intervention group
Group type: COMPARATOR
Intervention: Regular rice (80 g daily)
Number of subjects: 20
Study 22521214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100/325 mg for 7 days
Number of subjects: 75
Study 22521214 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 75
Study 20400201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg daily
Number of subjects: 127
Study 20400201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250mg/m(2) d 1, 8 q 21d)
Number of subjects: 127
Study 20400201 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75mg/m(2) d 1 q 21d)
Number of subjects: 127
Study 19026883 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ with accelerator (A+)
Number of subjects: 50
Study 19026883 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoREZ without accelerator (A-)
Number of subjects: 50
Study 19026883 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (Group 5)
Number of subjects: 50
Study 19026883 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (Group 6)
Number of subjects: 50
Study 15876903 — intervention group
Group type: EXPERIMENTAL
Intervention: H. perforatum (900-1500 mg/d)
Number of subjects: 340
Study 15876903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/d)
Number of subjects: 340
Study 15876903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 12830007 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (50 microg/h)
Number of subjects: 19
Study 12830007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11291022 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment approaches to memory loss, typically using Alzheimer's dementia as the template.
Number of subjects: 0
Study 8676532 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) continuously throughout the postoperative period
Number of subjects: 14
Study 8676532 — intervention group
Group type: COMPARATOR
Intervention: Saline as postoperative fluid therapy
Number of subjects: 14
Study 1338584 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Athletic Performance System (CAPS)
Number of subjects: 11
Study 1338584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dicalcium phosphate)
Number of subjects: 11
Study 31026086 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural oxycodone 0.1 mg kg‐1 and intravenous saline (EPI-group n = 31)
Number of subjects: 60
Study 31026086 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxycodone 0.1 mg kg‐1 and epidural saline (IV-group n = 29)
Number of subjects: 60
Study 27111084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine patch monotherapy
Number of subjects: 147
Study 27111084 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with memantine
Number of subjects: 147
Study 26194955 — intervention group
Group type: COMPARATOR
Intervention: Healthy living focused intervention (HL)
Number of subjects: 86
Study 26194955 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-focused intervention (AF)
Number of subjects: 86